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Abstract
Objective: Toestimate thehealth impact,financial costs, andcost-effectivenessof
scaling-upcoverageofhumanpapillomavirus(HPV)vaccination(younggirls)andcer-











effective, and a comprehensive program could avert 5.2 million cases, 3.7 million
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1  | INTRODUCTION
Despite the availability of both primary and secondary prevention,
anestimated528000womenworldwidedevelopedcervical cancer
in 2012, and 266 000 died from the disease.1Primaryprevention is
available in the form of effective prophylactic vaccines against the
oncogenichumanpapillomavirus(HPV)genotypesthatcauseapprox-
imately 70% (bivalent and quadrivalent vaccines) to 90% (9-valent
vaccine) of cervical cancers.2–5 For women beyond the target age 
of adolescentvaccination, secondarypreventionwith screening can
detect and treat precancerous lesions caused by oncogenic HPV
beforeprogressiontoinvasivecancer.Yettheseopportunitiesforpre-
ventionarenotreachingwomeninpoorcountries,where85%ofthe
cervical cancer burden resides.
TheWHOrecommendsHPVvaccinationforgirlsaged9–13years,
prior to initiation of sexual activity.6 For screening, the WHO 
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recommends that cervical cancer screening programs should priori-
tizewomenaged30–49years,astheriskofcervicalcancerrisesafter
age30years.TheWHOrecommendationsnotethatsetting-specific
screening intervals and frequency will depend upon availability of 
fundsandinfrastructure,andthatscreeningevenonceinalifetime—
with treatment if needed—is beneficial. While organized screening
withPapanicolaou(Pap)testinghasreducedtheincidenceofandmor-
tality attributable to cervical cancer inmanyhigh-incomecountries,
Paptestingislogisticallydifficultinlow-resourcesettings.Itrequires
costlylaboratoryinfrastructureandmultiplevisitsforscreening,diag-
nosis, and treatment.Thus,where sufficient resourcesareavailable,
theWHOrecommendsscreeningwithHPVtesting todetectonco-
genic infections,with prompt linkage to treatment forwomenwho
testpositive.Forsettingswithfewerresources,visualinspectionwith
aceticacid(VIA)—alesssensitivebutlow-costtestthatinvolvesappli-
cationof aceticacid (vinegar) to the cervix todetect abnormalities,
yieldingan immediateresult—isrecommended,andcanbefollowed







10–20 years had been vaccinated as of October 2014.7 Momentum 
appears to be increasing asGavi,TheVaccineAlliance—an interna-
tionalpublic–privatepartnershipaimingtoimproveaccesstonewand
underused vaccines in 54 eligible countries8—beganacceptingappli-
cationsforHPVvaccinessupportin2012.Gavihassincenegotiated









tries have introducedVIA pilot programs or includeVIA in national
guidelines, coverage remains low.13
To evaluate any policy intervention, decision makers require
information on feasibility, acceptability, financing, and value for
money.Atthiscriticaljunctureforcervicalcancerpreventionefforts,
we sought to provide information to those making immunization
andscreeningpolicyrecommendations,includingtheWHO,financ-
ing mechanisms, donors, and country governments. Our objective
wastoestimate,forcountriesthatwilllikelyneeddonorassistance,
thefinancialcostsandcost-effectivenessofscaling-upcoverageof
HPVvaccination foryoung girls and cervical cancer screening and






We used amodel-based approach to synthesize population, demo-
graphic, and epidemiological data from 50 low- and lower-middle-
income(LIandLMI)countrieswithpopulationsover1millionpersons
and gross national income (GNI) per capita less than or equal to
US $2585 (Supplementary material Tables S1 and S2); this represents 
the midpoint GNI per capita of the World Bank LMI country income 
tier,14 and henceforth we refer to LMI countries with a GNI per capita 
below this midpoint as “LMI1.” The Excel-based CERVIVAC model
describedinthenextsectionwasusedtoprojectthecostsandlifetime




theCERVIVACmodel (including vaccinedoses and service delivery;
direct medical costs of screening, diagnosis, and treatment of precan-
cer; and direct medical costs of cervical cancer treatment by stage) 
from the literature, using previously described methods.15We esti-
matedcountry-specificepidemiologicdatainputsonburdenofHPV,
precancer, and cervical cancer by applying previously described meth-
ods,15using:(1)multivariateregressionmodelstopredictcountry-and
age-specificHPVprevalence(SupplementarymaterialTableS3)15; (2) 
a peer-reviewed individual-based microsimulation model that was
previouslycalibratedtofourseparatelow-andlower-middle-income
countries (El Salvador, India, Nicaragua, and Uganda)16–18 to predict 
country-specificprevalenceofprecancer15; and (3) GLOBOCAN 2012 
toinformcountry-andage-specificcervicalcancerincidenceandmor-
tality (Supplementary material Tables S4 and S5).1 To estimate the
effectivenessofHPV-16/18vaccination,wereliedonvaccinetrialdata
andepidemiologicdataontheproportionofcervicalcancersattributed
to HPV-16/18.5,19–21 CERVIVAC inputs pertaining to screening and
treatmenteffectivenesswerederivedfromthemicrosimulationmodel,
whichwasusedtoestimatethereductioninage-specificcervicalcan-
cer incidenceandmortality, aswell as shifts in stagedistributionof
detected cervical cancer, associated with each screening strategy. We 
estimated current access to cancer treatment in each countryusing





(2017–2026). Because girls aged 10 years would not be subsequently 
eligibleforscreeningduringtheinterventionperiod,wedidnotexam-
ine the impact of screening in vaccinated women. We present both 
undiscounted costs and future costs discounted at an annual rate 
of3%in2013US$.Healthbenefitsarereportedascervicalcancer
cases,deaths,anddisability-adjustedlifeyears(DALYs)averted;DALYs
have been discounted at an annual rate of 3%. We present incremental 
cost-effectivenessratios(ICERs)—asthenetcostperDALYavertedto
accountforcancertreatmentoffsets—separatelyforvaccinationand
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screening(relativetonointervention).Whilethereisnouniversalcri-











cerous lesions, and cervical cancer treatment. The model, programmed 
usingMicrosoftExcelandVisualBasicforApplications2007(Microsoft
Corporation,Redmond,WA,USA),tracksmultiplebirthcohortsstart-
ing at a target age (i.e. 10years for HPV vaccination; 35years for
screening),projectingcostoutcomesbycountingresourceutilization
eventsandmultiplyingthesebyacountry-specificunitcost.
The HPV vaccination module counts the cost of vaccine doses
and service delivery costs. The screening module counts the costs of 
screening visits, treatment with cryotherapy, and—for women inel-
igible for cryotherapy—colposcopy and loop electrosurgical excision
procedures (LEEP); resource utilization is driven by screening test
sensitivityandspecificity,HPVprevalence,andtheprevalenceofpre-
cancer.Thecancertreatmentmodulecountsstage-specifictreatment
costs for local, regional, and distant cancers.
The number of females alive in each of the 50 countries, in each sin-
gleyearofage,wasbasedonthe2015UnitedNationsWorldPopulation
Prospects.24Eachbirthcohortwastrackedoveritslifetimetocapture
health service utilization, burden of disease, and long-term health
impactofvaccinationandscreeningduringtheinterventionperiod.








The health impact of screening was based on the screening test 
anditsperformancecharacteristics(SupplementarymaterialTableS6).
Wemadethefollowingsimplifyingassumptionsacrossallcountries:




with no lesion and 25% of women with cervical intraepithelial neopla-


















linear increases of 20% per year, beginning at 20% coverage in 2017 and reaching full coverage (100%) in 2021. We then assumed a gradual 
replacementwithHPV-basedscreening,whichreplacedVIAin10%ofthepopulationin2022andincreasedlinearlytocover50%ofthe
screening-eligiblepopulationby2026.[Colourfigurecanbeviewedatwileyonlinelibrary.com]
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For each screening test, we used the microsimulation model to
estimate percent reductions in age-specific cervical cancer incidence
andmortality(in5-yearagegroupsfromage20toage84years)attrib-
utable to a screening program with the features described above (e.g. 
treatmenteffectiveness,eligibilityforcryotherapy,etc).Descriptionsof
thismicrosimulationmodelandtheparameterizationprocess(including
model calibration to epidemiologic data for thedevelopmentof four
country-specificmodels reflectingthenaturalhistoryofcervicalcan-
cer in El Salvador, India, Nicaragua, and Uganda) have been previously 
published.16–18 Inbrief,weestimatedbaseline“prior”inputvaluesfor
naturalhistory transitionsusing longitudinaldata.25–28To reflecthet-
erogeneityinage-andtype-specificHPVincidencebetweensettings,
aswellasnatural immunityfollowing initial infectionanduncertainty
in progression and regression of precancer, we set plausible ranges 
around these input values. We then performed repeated model sim-
ulationsintheabsenceofanyintervention,selectingasinglerandom
























The health impact of cervical cancer treatment was used for 
DALY calculations. We used country-specific access to radiation
therapy infrastructure as a proxy for access to treatment at any
stage, given that most women with cervical cancer present with 
regionalcancerintheabsenceoforganizedscreening.22 For coun-
trieswithnodataonradiationtherapyinfrastructure,weassumed
no current access to cancer treatment at any stage (Supplementary 
materialTableS9).Weassumedthattheproportionofwomenwith
access to treatment in a country received the stage-specific stan-
dardof carebasedon the InternationalFederationofGynecology
andObstetrics(FIGO)guidelinesandaccordinglyhad5-yearrelative
survival rates resembling the US Surveillance, Epidemiology, and 
End Results Program: 92% for local, 57% for regional, and 17% for 
distant cancer.28Weassumed that theproportionofwomenwho
hadnoaccesstocancertreatmenthad5-yearabsolutesurvivalrates
based on a linear regression of survival in the IARC SurvCan data-
base and access to radiation therapy22,29 (65% for local, 37% for 
regional,and16%fordistantcancers). Inasensitivityanalysis,we
assumed all women with cancer had access to treatment based on 
the FIGO guidelines.
2.4 | Costs
All costs were converted to 2013 US $, and we assumed that inter-
ventioncostsdidnotvarywithcoverage level.Forvaccination,we
assumedthepriceof$4.50perdoseforGavi-eligiblecountriesandthe
PAHO Revolving Fund Price of $8.50 per dose for the four remaining 
countries (Bolivia,Honduras,RepublicofMoldova,andUzbekistan).
We estimated the country-specific HPV vaccine delivery cost per
dose as previously described (Supplementary material Tables S10 and 
S11).15Forscreening-relatedcosts,weincludedthecountry-specific
direct medical costs associated with screening, diagnosis (if relevant), 
and treatment of precancer, as previously described (Supplementary 
material Tables S12–S14).15
Cancer treatment costs were similarly derived for each country, 
assuming stage-specific treatment protocols based on FIGO guide-
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intervention period (2017–2026) is presented in Table1 for all 50
countries considered; results are also presented separately for India 
in Supplemental material Table S17. An HPV vaccination targeting
young girls and scaling up at a rate of 10% per year would reach an 
estimated163milliongirls in low-incomeand lower-middle-income
tier1countries.HPVvaccinationduringa10-yearinterventionperiod
wouldavertanestimated3.3millioncervicalcancercases,2.4million
deaths, and 9.5millionDALYs over the lifetimes of the vaccinated
cohorts.
Ascreeningprogramreachingfullscalewithinthefirst5years
of the intervention periodwould reach an estimated 170 million
women. Screening efforts during a 10-year intervention period
would avert an estimated 1.9 million cervical cancer cases, 1.3
million deaths, and 12.6 million DALYs over the lifetimes of the
screened cohorts.
3.2 | Cost and cost- effectiveness
Total costs for the HPV vaccination program and cervical cancer






in cervical cancer treatment costs were averted. As a result, the net 
costofanHPVvaccinationprogramremainedhighatUS$1.70billion.
The program cost per vaccinated girl was US $14.15 (undiscounted), 
whilethenetcostperDALYavertedwasUS$179(discounted).
The total cost of a screening program for women aged 35 years, 
reaching full coverage during the first 5years of the intervention
period,was US$1.28 billion (discounted). Cancer treatment offsets
wereapproximately38%oftotalprogramcosts; thenetcostof the
screening program was US $799 million. The program cost per woman 
reachedwasUS$8.88,andthenetcostperDALYavertedwasUS$64.
While we report the aggregated results across all countries in each 
incometier,theICERforHPVvaccinationwasbelowcountrypercap-





access to cancer treatment are presented in Supplementary material 
Table S18. As more cancer treatment costs were averted, the net cost 
perDALYavertedfromHPVvaccinationbecamemoreattractive.The
netcostassociatedwithscreeningbecamenegative,asthescreening










a comprehensive program could avert 5.2 million cases, 3.7 million 
deaths, and 22.0millionDALYs over the lifetimes of the interven-
tioncohortsforatotal10-yearprogramcostofUS$3.2billion(dis-
counted). We note that the program cost per woman reached was 
higherforvaccinationthanforscreeningbecausethecostoftwovac-
cine doses and the delivery cost per dose tended to be higher than 
thecostofscreeningwitheitherVIAorHPVtesting.Whilevaccina-
tion avertedmore cervical cancer cases and deaths than screening
overthelifetimeoftheinterventioncohorts(despiteaslowerroll-out
forvaccination),DALYsavertedwerehigherwithscreeningowingto
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economic impact of cervical cancer screening aggregated across coun-
triesinLMICs,amodelingstudyfoundPaptestingandVIAtobevery
cost-effective in theWHOsub-regionsofSub-SaharanAfrica (AfrE)
and South East Asia (SearD).32Country-contextualizedanalyseshave












primary data sources used; we assumed these generally represented 
financialcosts.Weassumedthefourcountriesthatwerenoteligible
forsupportfromGaviwouldbeabletoprocuretheHPVvaccineat
a price similar to that of the PAHO Revolving Fund, which may not 
be true for the two that are not PAHO member states. We also did 
notexplicitlyconsiderHIVburden in thisanalysis.Ourestimatesof
vaccine impact do not account for indirect protection due to herd
immunityamongunvaccinatedgirls,andthusmayunderestimatethe
health benefits of HPV vaccination. To account for herd immunity
benefits,HPVtransmissionmodelsinformedbysexualbehaviordata
are needed.Wehave not explored the impact ofvarying coverage,
vaccineefficacy,screeningtestperformance,orvisitcompliancehere,
but have described elsewhere the importance of these parameters in 
estimatingthecost-effectivenessofcervicalcancerprevention.33,34
Whileourassumptionof scale-up to100%coverageof the tar-
getpopulationsandperfectcompliancewithvaccinationorscreening
arenotrealistic,webelievetheestimatesofcostandhealth impact
represent anupper boundon the requiredfinancial outlays (froma
payer’sperspective) forcervicalcancerprevention inLMICs.Asoci-
etalperspectivewouldbeneeded to captureall costs regardlessof
payer,includingwomen’scostsfortimeandtransportation,whichcan
besubstantialinlow-resourcesettings.35 Due to lack of data, we have 
not included programmatic costs for infrastructural improvements,
whichmaybesubstantial.Bynot including these importantsocietal
costs,we are likely underestimating the economic costs of cervical
cancerprevention.On theotherhand,becauseweassumedcancer




we assumed all women with cancer had access to the standard of care. 




In 2015, US $36.4 billion in development assistance for health was 
disbursed.36Ofthis,US$10.8billionwasforHIV/AIDS,US$6.5billion
was for child and newborn health, and US $3.6 billion was for maternal 
health. While development assistance for health has increased mark-
edly since 2000,36cancerpreventionandtreatmentinLMICshasbeen
underfunded,resultinginanestimated5%ofglobalcancerresources
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